ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 102 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,304,792 | +14.5% | 241,846 | +32.1% | 0.00% | 0.0% |
| Q1 2023 | $2,013,165 | -18.2% | 183,015 | +10.0% | 0.00% | 0.0% |
| Q4 2022 | $2,462,395 | -2.4% | 166,378 | +26.1% | 0.00% | -33.3% |
| Q3 2022 | $2,522,000 | -13.4% | 131,979 | -3.5% | 0.00% | 0.0% |
| Q2 2022 | $2,913,000 | +17.0% | 136,724 | +5.8% | 0.00% | +50.0% |
| Q1 2022 | $2,490,000 | -1.7% | 129,276 | +5.9% | 0.00% | 0.0% |
| Q4 2021 | $2,532,000 | -13.2% | 122,097 | +0.0% | 0.00% | -33.3% |
| Q3 2021 | $2,916,000 | -11.7% | 122,087 | +0.7% | 0.00% | 0.0% |
| Q2 2021 | $3,304,000 | -4.6% | 121,216 | +1.3% | 0.00% | 0.0% |
| Q1 2021 | $3,462,000 | – | 119,670 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |